Virtual healthcare: how the COVID-19 pandemic is driving the rise of telemedicine

How has COVID-19 transformed telemedicine from an optional tool into a necessity? Dr Ray Dorsey describes the current state and impact of virtual healthcare.

  1. Dorsey R, Sherer T, Okun MS, Bloem BR. Ending Parkinson's Disease: A Prescription for Action. Hachette Book Group; 2020.  https://www.amazon.com/Ending-Parkinsons-Disease-Prescription-Action/dp/1541724526 and https://books.google.com/books/about/Ending_Parkinson_s_Disease.html?id=TVShDwAAQBAJ&source=kp_book_description

Dr E. Ray Dorsey has received honoraria for speaking at American Academy of Neurology courses, American Neurological Association, and University of Michigan; received compensation for consulting services from 23andMe, Abbott, Abbvie, American Well, Biogen, Clintrex, Curasen Therapeutics, DeciBio, Denali Therapeutics, GlaxoSmithKline, Grand Rounds, Karger, Lundbeck, MC10, MedAvante, Medical-legal services, Mednick Associates, National Institute of Neurological Disorders and Stroke, Olson Research Group, Optio, Origent Data Sciences, Inc., Prilenia, Putnam Associates, Roche, Sanofi, Shire, Sunovion Pharma, Teva, UCB and Voyager Therapeutics; research support from Abbvie, Acadia Pharmaceuticals, AMC Health, Biosensics, Burroughs Wellcome Fund, Davis Phinney Foundation, Duke University, Food and Drug Administration, GlaxoSmithKline, Greater Rochester Health Foundation, Huntington Study Group, Michael J. Fox Foundation, National Institutes of Health/National Institute of Neurological Disorders and Stroke, National Science Foundation, Nuredis Pharmaceuticals, Patient-Centered Outcomes Research Institute, Pfizer, Prana Biotechnology, Raptor Pharmaceuticals, Roche, Safra Foundation, Teva Pharmaceuticals, University of California Irvine; editorial services for Karger Publications; and ownership interests with Blackfynn (data integration company) and Grand Rounds (second opinion service).